Summit Master_rgb_png.png
Summit Enrols Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DMD
November 16, 2016 07:00 ET | Summit Therapeutics PLC
OXFORD, United Kingdom, Nov. 16, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Master_rgb_png.png
Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
October 04, 2016 07:01 ET | Summit Therapeutics PLC
OXFORD, United Kingdom, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Master_rgb_png.png
Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
October 04, 2016 07:00 ET | Summit Therapeutics PLC; Sarepta Therapeutics
Sarepta and Summit collaborate to advance the development of novel therapies for patients with Duchenne muscular dystrophySummit receives $40 million upfront, with potential future ezutromid-related...
Summit Master_rgb_png.png
Summit Receives Rare Pediatric Disease Designation From US FDA for Ezutromid in Treatment of Duchenne Muscular Dystrophy
September 27, 2016 07:00 ET | Summit Therapeutics PLC
OXFORD, United Kingdom, Sept. 27, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Master_rgb_png.png
Summit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy Community
September 12, 2016 07:00 ET | Summit Therapeutics PLC
OXFORD, United Kingdom, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Master_rgb_png.png
First Patient Enrolled in Summit’s PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys With DMD
June 17, 2016 07:00 ET | Summit Therapeutics PLC
OXFORD, United Kingdom, June 17, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Master_rgb_png.png
Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
May 10, 2016 07:00 ET | Summit Therapeutics plc
OXFORD, United Kingdom, May 10, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Master_rgb_png.png
Summit Announces Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMD
March 15, 2016 07:00 ET | Summit Therapeutics plc
OXFORD, United Kingdom, March 15, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Master_rgb_png.png
Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD
January 21, 2016 07:00 ET | Summit Therapeutics plc
OXFORD, UK, Jan. 21, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’)...
Prosensa Holding B.V. Logo
Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy
September 08, 2014 08:00 ET | Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) -- LEIDEN, The Netherlands - September 8, 2014 - Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating...